Caen Cedex 5

• HARMONi-3 Not authorised
  2023-504989-37-00 5 Metastatic Squamous Non-small Cell Lung Cancer
• Single-arm, multicenter, phase II study of immunotherapy in patients with type B3 thymoma and thymic carcinoma previously treated with chemo … Pending
  2023-508658-24-00 4 type B3 thymoma and thymic carcinoma
• Study of the effect and tolerability of INT230-6 by direct injection into the tumor, followed by neoadjuvant treatment with chemoimmunothera … Pending
  2024-512511-49-00 4 Early triple-negative breast cancer (TNBC)
• Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable high grade gliomas patients Pending
  2024-514144-85-02 3 Glioblastoma
• LEAn Body Mass Normalization of OXaliplatin Based Chemotherapy Pending
  2024-515340-23-00 4 Colon cancer
• TALazoparib and Avelumab as maintenance therapy in platinum-Sensitive metastatic or locally advanced URothelial carcinoma: A single-arm Phas … Pending
  2024-516182-37-01 4 Maintenance treatment in patients with locally advanced/metastatic uro
• Evaluating a Personalized Treatment Strategy for Young Women with Early Breast Cancer Pending
  2024-519655-28-00 5 Premenopausal patients with high-risk HR-positive/HER2-negative breast
• Evaluation study of a treatement with Nivolumab and Ipilimumab or tKi according to molecular group in naïve metastatic Kidney cancer Pending
  2024-520045-23-00 4 Kidney cancer
• DAREON®-Lung-1: A study in people with advanced small cell lung cancer to compare obrixtamig plus atezolizumab, carboplatin, and etoposide t … Pending
  2025-520565-51-00 5 small cell lung cancer
• Phase II study of ficerafusp alfa in combination with nivolumab in patients with platinum-refractory head and neck squamous cell carcinoma w … Pending
  2025-521437-88-00 4 head and neck squamous cell carcinoma
• Impact of the timing of immunotherapy administration in metastatic lung cancers Pending
  2025-521891-78-00 5 Adult patients with stage IV non squamous non-small cell lung cancer (
• Testing two different drugs (sacituzumab-govitecan and trastuzumab-deruxtecan) combinations prescribed in an alterning pattern to patients w … Pending
  2025-521909-40-00 4 Patients with metastatic or locally advanced HER2-low triple-negative
• A Study of Vepugratinib (LY3866288) in Participants with Cancer in the Urinary Tract ( FORAGER-2 ) Pending
  2025-522855-25-00 5 Carcinoma, Transitional Cell
• Skipping Hormone Therapy in Low-Risk Early Breast Cancer Pending
  2025-523683-20-00 4 Postmenopausal patients with small (pT1a-b pN0) hormone receptor posit
• Phase 3 study comparing ivonescimab alone or ivonescimab with ligufalimab versus pembrolizumab for the first-line treatment of recurrent and … Recruiting
  2025-522996-27-00 5 2026-05-05 recurrent and/or metastatic squamous cell carcinoma of the head and ne
• Trial of T-DXd Versus SoC Chemotherapy as Adjuvant Treatment in Endometrial Cancer Recruiting
  2024-519444-33-00 5 2026-03-12 HER2-expressing endometrial cancer (IHC 3+/2+)
• A clinical study of sacituzumab tirumotecan for cervical cancer (MK-2870-036) Recruiting
  2025-521514-26-00 5 2026-01-26 Persistent, Recurrent, or Newly Diagnosed Metastatic Cervical Cancer W
• A clinical study of the anti-cancer effects of an investigational therapy or chemotherapy in patients with recurring uterine cancer Recruiting
  2023-507525-42-00 5 2025-12-23 Endometrial cancer
• NoLEEta - Phase III non-inferiority trial of chemotherapy de-escalation in hormone receptorpositive, Her2-negative, intermediate-risk early … Recruiting
  2025-520979-13-00 5 2025-12-18 Patients with HR+ HER2- early breast cancer at intermediate risk of re
• Dato-DXd plus Carboplatin or Cisplatin versus Gemcitabine plus Carboplatin or Cisplatin in Previously Treated la/mUC. Recruiting
  2024-516906-47-00 10 2025-11-28 Locally Advanced or Metastatic Urothelial Carcinoma
• HER2DX-guided diagnostic treatment For patients with HER2-positive early-stage breast cancer Recruiting
  2025-521040-37-00 5 2025-11-26 HER2-positive early breast cancer
• A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab vs Chemotherapy plus Pembrolizumab as First-Line Treatment o … Recruiting
  2023-508056-19-00 5 2025-10-02 HER2-Expressing (IHC 3+/IHC 2+), Mismatch Repair Proficient (pMMR), P
• A PHASE 2 STUDY TO RESEARCH THE SAFETY AND EFFICACY OF TRASTUZUMAB DERUXTECAN VERSUS CDK4/6I PLUS ENDOCRINE THERAPY IN ADVANCED BREAST CANCE … Recruiting
  2024-512360-55-00 4 2025-06-30 Unresectable locally recurrent or metastatic hormone receptor (HR)-pos
• A Study to see How Well and How Safely Different Treatments Work in a Group of Patients with Non-Small Cell Lung Cancer, Chosen Based on the … Recruiting
  2024-511239-91-00 4 2025-05-05 Resectable Stage I-III Non-Small Cell Lung Cancer (NSCLC)

Showing 1–24 of 283 trials